Stay updated on Pralsetinib in RET+ Cancer Clinical Trial

Sign up to get notified when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pralsetinib in RET+ Cancer Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The page now indicates that results have been submitted, replacing the previous message that no results were posted.
    Difference
    0.1%
    Check dated 2025-03-25T14:08:06.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    No Change Detected
  5. Check
    30 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-02-24T21:16:40.000Z thumbnail image
  6. Check
    44 days ago
    Change Detected
    Summary
    The page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for the Help Desk.
    Difference
    1%
    Check dated 2025-02-10T10:09:24.000Z thumbnail image
  7. Check
    51 days ago
    Change Detected
    Summary
    The website has been updated from version v2.14.1 to v2.14.2.
    Difference
    0.3%
    Check dated 2025-02-03T08:52:49.000Z thumbnail image
  8. Check
    58 days ago
    Change Detected
    Difference
    0.5%
    Check dated 2025-01-27T03:35:11.000Z thumbnail image
  9. Check
    66 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    0.0%
    Check dated 2025-01-19T22:32:31.000Z thumbnail image

Stay in the know with updates to Pralsetinib in RET+ Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.